Invivyd Förvaltning

Förvaltning kriterier kontrolleras 2/4

Invivyd VD är Bill Duke, utsedd i Sep 2023, har en mandatperiod på 2.58 år. totala årliga ersättningen är $ 2.14M, bestående av 22.7% lön 77.3% bonusar, inklusive företagsaktier och optioner. äger direkt 0.038% av företagets aktier, värda $ 180.97K. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 2.3 år respektive 2.9 år.

Viktig information

Bill Duke

Verkställande direktör

US$2.1m

Total ersättning

VD-lön i procent	22.65%
Anställning som VD	2.6yrs
Ägande av VD	0.04%
Ledningens genomsnittliga anställningstid	2.3yrs
Styrelsens genomsnittliga mandatperiod	2.9yrs

Senaste uppdateringar av ledningen

Recent updates

Invivyd: A Logical Bull Thesis With A Major Catalyst Approaching

Mar 20

Invivyd, Inc.'s (NASDAQ:IVVD) 26% Share Price Plunge Could Signal Some Risk

Jan 29

Optimistic Investors Push Invivyd, Inc. (NASDAQ:IVVD) Shares Up 27% But Growth Is Lacking

Nov 29

Invivyd, Inc.'s (NASDAQ:IVVD) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Oct 14

Why Investors Shouldn't Be Surprised By Invivyd, Inc.'s (NASDAQ:IVVD) 31% Share Price Plunge

Aug 22

Analys av ersättningar till VD

Hur har Bill Duke:s ersättning förändrats jämfört med Invivyd:s resultat?
Datum	Total ersättning	Lön	Företagets resultat
Dec 31 2025	US$2m	US$485k	-US$52m
Sep 30 2025	n/a	n/a	-US$60m
Jun 30 2025	n/a	n/a	-US$110m
Mar 31 2025	n/a	n/a	-US$143m
Dec 31 2024	US$636k	US$480k	-US$170m

Ersättning vs marknad: Bill s total kompensation ($USD 2.14M ) är ungefär genomsnittet för företag av liknande storlek på US marknaden ($USD 2.44M ).

Ersättning vs inkomst: Ersättningen för Bill har ökat samtidigt som företaget är olönsamt.

VD OCH KONCERNCHEF

Bill Duke (53 yo)

2.6yrs

Anställning

US$2,141,222

Kompensation

Mr. William E. Duke, Jr., also known as Bill, M.B.A., serves as Chief Financial Officer and Principal Accounting Officer of Invivyd, Inc. since September 2023 and serves as its Principal Executive Officer...

Ledningsgrupp

Namn	Position	Anställning	Kompensation	Ägarskap
William Duke	CFO, Principal Accounting Officer & Principal Executive Officer	2.6yrs	US$2.14m	0.038% $ 181.0k
Jill Andersen	Chief Legal Officer & Corporate Secretary	4.4yrs	US$2.49m	0.064% $ 306.2k
Timothy Lee	Chief Commercial Officer	1.9yrs	US$2.10m	0.042% $ 197.7k
Robert Allen	Chief Scientific Officer	3yrs	US$2.16m	0.040% $ 192.3k
Kristie Kuhl	Chief Communications Officer	less than a year	inga uppgifter	inga uppgifter
Julie Green	Chief Human Resources Officer	3.3yrs	US$1.59m	0.038% $ 181.0k
Rachael Gerlach	Senior Vice President of Regulatory Affairs	less than a year	inga uppgifter	inga uppgifter
Katie Falzone	Senior Vice President of Finance	no data	inga uppgifter	inga uppgifter
Michael Mina	Chief Medical Officer	less than a year	inga uppgifter	inga uppgifter

2.3yrs

Genomsnittlig anställningstid

51.5yo

Genomsnittlig ålder

Erfaren ledning: IVVD s ledningsgrupp anses vara erfaren ( 2.3 års genomsnittlig anställningstid).

Styrelseledamöter

Namn	Position	Anställning	Kompensation	Ägarskap
Terrance McGuire	Independent Director	5.5yrs	US$84.46k	inga uppgifter
Kevin McLaughlin	Independent Director	1.9yrs	US$101.61k	0.018% $ 84.0k
Marc Elia	Independent Chairperson of the Board	3.8yrs	US$125.96k	inga uppgifter
Ajay Royan	Independent Director	1.1yrs	US$110.16k	inga uppgifter
Paul B. Bolno	Independent Director	less than a year	US$134.35k	inga uppgifter
Tamsin Berry	Independent Director	3.8yrs	US$87.96k	0% $ 0

2.9yrs

Genomsnittlig anställningstid

50yo

Genomsnittlig ålder

Erfaren styrelse: IVVD s styrelse anses inte vara erfaren ( 2.9 års genomsnittlig mandatperiod), vilket föreslår en ny styrelse.

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/04/21 15:11
Aktiekurs vid dagens slut	2026/04/21 00:00
Intäkter	2025/12/31
Årlig intjäning	2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Invivyd, Inc. bevakas av 6 analytiker. 4 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Thomas Shrader	BTIG
Joshua Schimmer	Cantor Fitzgerald & Co.
Jason Kolbert	D. Boral Capital LLC.

Invivyd Förvaltning

Förvaltning kriterier kontrolleras 2/4

Viktig information

Senaste uppdateringar av ledningen

Invivyd, Inc., Annual General Meeting, May 19, 2026

Invivyd, Inc. Appoints Michael Mina, M.D., Ph.D. As Chief Medical Officer

Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors

Invivyd, Inc. Appoints Kristie Kuhl as Chief Communications Officer

Invivyd, Inc., Annual General Meeting, May 20, 2025

Invivyd, Inc. Appoints Ajay Royan, to Its Board of Directors

Recent updates

Invivyd, Inc Announces Progress in Revolution Program and Advancement of Novel Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

Invivyd, Inc., Annual General Meeting, May 19, 2026

Invivyd: A Logical Bull Thesis With A Major Catalyst Approaching

Invivyd, Inc. Appoints Michael Mina, M.D., Ph.D. As Chief Medical Officer

Invivyd Aligns with the U.S. Fda on Liberty, A Phase 3 Trial to Evaluate the Safety of Vyd2311 Antibody Versus Mrna Covid Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine

Invivyd, Inc.'s (NASDAQ:IVVD) 26% Share Price Plunge Could Signal Some Risk

Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026

Optimistic Investors Push Invivyd, Inc. (NASDAQ:IVVD) Shares Up 27% But Growth Is Lacking

Invivyd, Inc. Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329

Invivyd, Inc. has completed a Follow-on Equity Offering in the amount of $124.9994 million.

Invivyd, Inc.'s (NASDAQ:IVVD) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Invivyd, Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application and Provide Feedback to Advance the Company's Revolation Clinical Program

Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors

Invivyd, Inc. Appoints Kristie Kuhl as Chief Communications Officer

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At Recover-TLC Workshop

Invivyd, Inc. has completed a Follow-on Equity Offering in the amount of $49.997866 million.

Why Investors Shouldn't Be Surprised By Invivyd, Inc.'s (NASDAQ:IVVD) 31% Share Price Plunge

Invivyd, Inc. has filed a Follow-on Equity Offering.

Invivyd, Inc. Announces Continued Neutralizing Activity of PEMGARDA®? (Pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG

Invivyd, Inc. Aligns with U.S. FDA on Rapid Pathway to Full Approval of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long Covid and Covid-19 Post-Vaccination Syndrome

Invivyd, Inc. Announces Positive Full Phase 1/2 Clinical Data for VYD2311, A Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

Invivyd Announces Publication of Landmark CANOPY Phase 3 Pemivibart Clinical Trial

Invivyd, Inc. Announces Inclusion of PEMGARDA (Pemivibart) in National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

Invivyd, Inc. Commends FDA Focus on Contemporary Evidence in Evaluating Medical Interventions to Prevent Covid-19

Invivyd, Inc. Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies for Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

Invivyd Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Pemivibart And Next-Generation VYD2311 Will Empower Market Expansion By 2025

Invivyd, Inc., Annual General Meeting, May 20, 2025

Invivyd, Inc. Appoints Ajay Royan, to Its Board of Directors

Invivyd, Inc. Auditor Raises 'Going Concern' Doubt

Invivyd, Inc. Announces Continued Neutralizing Activity of PEMGARDA™? (Pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

I See The Bull Case For Invivyd, But I'm Not Married To It

Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population

Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?

Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients

Invivyd, Inc. Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

Invivyd, Inc. Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Invivyd, Inc. Announces Resignation of Sara Cotter from the Board of Directors

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers

Invivyd, Inc. Withdraws Financial Guidance for the Year 2024

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows Pemgarda™ (Pemivibart) Provided Substantial Protection from Symptomatic Covid-19 Versus Placebo over Six Months of Follow-Up, with No Additional Doses, in Immunocompetent Participants

Invivyd, Inc. Announces U.S. FDA Has Updated the PEMGARDA EUA Fact Sheet with Accurate SARS-CoV-2 Variant Sensibility and PEMGARDA Activity Data

Invivyd, Inc. Doses First Participants in Phase 1 Clinical Trial of VYD2311, A Next Generation Monoclonal Antibody Candidate for COVID-19

Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial

Here's Why We're Watching Invivyd's (NASDAQ:IVVD) Cash Burn Situation

Invivyd Announces General Alignment with U.S. FDA on A Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies

Invivyd, Inc. Announces Management Changes

Invivyd, Inc. Elects Two New Independent Members to its Board of Directors

Forecast to breakeven in 2026

Invivyd, Inc. to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback

Invivyd, Inc., Annual General Meeting, May 21, 2024

Invivyd, Inc. Receives Healthcare Common Procedure Coding System Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services Covering Pemgarda

Invivyd, Inc. Announces CEO Changes

New minor risk - Profitability

No longer forecast to breakeven

Consensus revenue estimates fall by 13%

Invivyd, Inc. Provides Earnings Guidance for the Year 2024

Forecast breakeven date moved forward to 2025

Consensus revenue estimates increase by 64%

Is Invivyd (NASDAQ:IVVD) In A Good Position To Invest In Growth?

Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

New minor risk - Shareholder dilution

Forecast to breakeven in 2026

Invivyd, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Invivyd, Inc. Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19